Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorV, D. Rojas Mejia
dc.contributor.authorZWIENER, R. D.
dc.contributor.authorVILLA, R. Cardona
dc.contributor.authorRAMIREZ, L. F.
dc.contributor.authorESPINOSA, D. L. Silva
dc.contributor.authorZANACCHI, V. A.
dc.contributor.authorSOSA, P. Piraino
dc.contributor.authorENSINA, L. F.
dc.contributor.authorBIANCHI, P. Giavina
dc.contributor.authorPORTILHO, N. Coelho
dc.contributor.authorAUN, M. Vivolo
dc.contributor.authorBENAVIDES, E. Matos
dc.contributor.authorRUIZ, D. M. Martinez
dc.contributor.authorJARES, E.
dc.contributor.authorREYES, C. D. Serrano
dc.date.accessioned2024-02-15T14:39:32Z
dc.date.available2024-02-15T14:39:32Z
dc.date.issued2021
dc.description.abstractBackground: Severe cutaneous adverse reactions to drugs (SCARs) are associated with high morbidity and mortality and with sequelae. Objective: To characterize patients with SCARs in 8 health care institutions in Latin America. Methods: We performed a cross-sectional, descriptive, multicenter study of patients diagnosed with SCARs in Latin America between January 2009 and December 2018. The analysis was carried out using a database in BD Clinic. Results: We collected 70 patients, of whom 42 (60%) were women. Mean age was 38.7 years. Forty-two patients (60%) had DRESS-DIHS, 12 (17.1%) TEN, 5 (7.1%) SJS, 6 (8.5%) AGEP, 4 (5.7%) other reactions not classified as SCARs, and 1 (1.4%) overlapping SJS-TEN. The main causative drugs were aromatic anticonvulsants in 31 cases (44.3%), beta-lactam antibiotics in 11 cases (15.7%), and non-beta-lactam antibiotics in 6 cases (8.6%). In all of the cases, the suspected drug was withdrawn at the first sign of a SCAR. Sixty-six patients (94.2%) received anti-inflammatory treatment, mostly systemic corticosteroids. Complications occurred in 53 cases (75.7%), and 3 patients died (4.3%). Thirteen patients (18.6%) had sequelae. Conclusions: This is the first multicenter report on SCARs in Latin America. DRESS-DIHS was the most frequently reported clinical entity, and anticonvulsants were the main triggers. Most of the patients received systemic corticosteroids. Complications were frequent, and 3 patients died.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationJOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, v.31, n.4, p.322-331, 2021
dc.identifier.doi10.18176/jiaci.0497
dc.identifier.eissn1698-0808
dc.identifier.issn1018-9068
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57866
dc.language.isoeng
dc.publisherESMON PUBLICIDAD S A, DEPT ALLERGY & CLIN IMMUNOL, CLIN UNIV NAVARRAeng
dc.relation.ispartofJournal of Investigational Allergology and Clinical Immunology
dc.rightsopenAccesseng
dc.rights.holderCopyright ESMON PUBLICIDAD S A, DEPT ALLERGY & CLIN IMMUNOL, CLIN UNIV NAVARRAeng
dc.subjectDrug eruptionseng
dc.subjectStevens-Johnson syndromeeng
dc.subjectToxic epidermal necrolysiseng
dc.subjectDRESSeng
dc.subjectAcute generalized exanthematous pustulosiseng
dc.subjectLatin Americaeng
dc.subject.othertoxic epidermal necrolysiseng
dc.subject.otherstevens-johnson-syndromeeng
dc.subject.othergeneralized exanthematous pustulosiseng
dc.subject.othersystemic symptoms dresseng
dc.subject.otherintravenous immunoglobulineng
dc.subject.otherantiepileptic drugseng
dc.subject.otherpediatric-patientseng
dc.subject.otherburn uniteng
dc.subject.othereosinophiliaeng
dc.subject.otherhypersensitivityeng
dc.subject.wosAllergyeng
dc.subject.wosImmunologyeng
dc.titleSevere Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Studyeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countryArgentina
hcfmusp.affiliation.countryPeru
hcfmusp.affiliation.countryParaguai
hcfmusp.affiliation.countryisope
hcfmusp.affiliation.countryisoco
hcfmusp.affiliation.countryisoar
hcfmusp.affiliation.countryisopy
hcfmusp.author.externalV, D. Rojas Mejia:Univ Icesi, Fdn Valle Lili, Cali, Colombia
hcfmusp.author.externalZWIENER, R. D.:Hosp Univ Austral, Buenos Aires, DF, Argentina
hcfmusp.author.externalVILLA, R. Cardona:Univ Antioquia, Medellin, Colombia
hcfmusp.author.externalRAMIREZ, L. F.:Univ Icesi, Fdn Valle Lili, Cali, Colombia
hcfmusp.author.externalESPINOSA, D. L. Silva:Univ Icesi, Fdn Valle Lili, Cali, Colombia
hcfmusp.author.externalZANACCHI, V. A.:Hosp San Roque Cordoba, Cordoba, Argentina
hcfmusp.author.externalSOSA, P. Piraino:Hosp Cent, Asuncion, Paraguay
hcfmusp.author.externalENSINA, L. F.:Univ Fed Sao Paulo UNIFESP, Sao Pablo, Brazil
hcfmusp.author.externalBENAVIDES, E. Matos:Inst Nacl Salud Nino, Lima, Peru
hcfmusp.author.externalRUIZ, D. M. Martinez:Univ Icesi, Fdn Valle Lili, Cali, Colombia
hcfmusp.author.externalJARES, E.:Fdn LIBRA, Buenos Aires, DF, Argentina
hcfmusp.author.externalREYES, C. D. Serrano:Univ Icesi, Fdn Valle Lili, Cali, Colombia
hcfmusp.citation.scopus5
hcfmusp.contributor.author-fmusphcPEDRO FRANCISCO GIAVINA-BIANCHI JUNIOR
hcfmusp.contributor.author-fmusphcNATHALIA COELHO PORTILHO KELMANN
hcfmusp.contributor.author-fmusphcMARCELO VIVOLO AUN
hcfmusp.description.beginpage322
hcfmusp.description.endpage331
hcfmusp.description.issue4
hcfmusp.description.volume31
hcfmusp.origemWOS
hcfmusp.origem.pubmed32101172
hcfmusp.origem.scopus2-s2.0-85111780762
hcfmusp.origem.wosWOS:000677683400005
hcfmusp.publisher.cityBARCELONAeng
hcfmusp.publisher.countrySPAINeng
hcfmusp.relation.referenceAires DJ, 2013, J DRUGS DERMATOL, V12, P679eng
hcfmusp.relation.referenceAl-Shouli S, 2005, ACTA DERM-VENEREOL, V85, P534, DOI 10.1080/00015550510037062eng
hcfmusp.relation.referenceAlvarado SA, 2018, ANN ALLERG ASTHMA IM, V121, P552, DOI 10.1016/j.anai.2018.05.022eng
hcfmusp.relation.referenceBachot N, 2003, ARCH DERMATOL, V139, P33, DOI 10.1001/archderm.139.1.33eng
hcfmusp.relation.referenceBastuji-Garin S, 2000, J INVEST DERMATOL, V115, P149, DOI 10.1046/j.1523-1747.2000.00061.xeng
hcfmusp.relation.referenceBASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92eng
hcfmusp.relation.referenceBlaszczyk B, 2015, PHARMACOL REP, V67, P426, DOI 10.1016/j.pharep.2014.11.009eng
hcfmusp.relation.referenceBotelho LFF, 2016, INT J DERMATOL, V55, pE198, DOI 10.1111/ijd.13126eng
hcfmusp.relation.referenceCarrillo D. ZL, 2012, REV ASOC COLOMB DERM, V20, P330eng
hcfmusp.relation.referenceChafranska L, 2019, PEDIATR DERMATOL, V36, P342, DOI 10.1111/pde.13778eng
hcfmusp.relation.referenceChen YC, 2010, ARCH DERMATOL, V146, P1373, DOI 10.1001/archdermatol.2010.198eng
hcfmusp.relation.referenceChiou CC, 2008, J EUR ACAD DERMATOL, V22, P1044, DOI 10.1111/j.1468-3083.2008.02585.xeng
hcfmusp.relation.referenceChua GT, 2018, EUR ANN ALLERGY CLIN, V50, P273, DOI 10.23822/EurAnnACI.1764-1489.47eng
hcfmusp.relation.referenceChung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859eng
hcfmusp.relation.referenceDavidovici B, 2008, ISR MED ASSOC J, V10, P410eng
hcfmusp.relation.referenceDemoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.xeng
hcfmusp.relation.referenceFischer M, 2002, BRIT J DERMATOL, V146, P707, DOI 10.1046/j.1365-2133.2002.46833.xeng
hcfmusp.relation.referenceGaitanis G, 2012, DERMATOLOGY, V224, P134, DOI 10.1159/000338202eng
hcfmusp.relation.referenceGanzetti G, 2015, GIORN ITAL DERMAT V, V150, P467eng
hcfmusp.relation.referenceGilbert M, 2018, DERMATOL THEReng
hcfmusp.relation.referenceGuevara-Gutierrez E, 2009, INT J DERMATOL, V48, P253, DOI 10.1111/j.1365-4632.2009.03908.xeng
hcfmusp.relation.referenceHALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001eng
hcfmusp.relation.referenceHiransuthikul A, 2016, ALLERGOL INT, V65, P432, DOI 10.1016/j.alit.2016.04.001eng
hcfmusp.relation.referenceHunger RE, 2005, J ALLERGY CLIN IMMUN, V116, P923, DOI 10.1016/j.jaci.2005.06.029eng
hcfmusp.relation.referenceJevtovic D, 2005, HIV MED, V6, P140, DOI 10.1111/j.1468-1293.2005.00277.xeng
hcfmusp.relation.referenceKardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.xeng
hcfmusp.relation.referenceKardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501eng
hcfmusp.relation.referenceKreft B, 2010, J DERMATOL, V37, P904, DOI 10.1111/j.1346-8138.2010.00893.xeng
hcfmusp.relation.referenceLee HY, 2012, BRIT J DERMATOL, V167, P555, DOI 10.1111/j.1365-2133.2012.11074.xeng
hcfmusp.relation.referenceLi LF, 2006, CLIN EXP DERMATOL, V31, P642, DOI 10.1111/j.1365-2230.2006.02185.xeng
hcfmusp.relation.referenceMcCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297eng
hcfmusp.relation.referenceMcCullough M, 2017, BURNS, V43, P200, DOI 10.1016/j.burns.2016.07.026eng
hcfmusp.relation.referenceMisirlioglu ED, 2017, J ALLER CL IMM-PRACT, V5, P757, DOI 10.1016/j.jaip.2017.02.013eng
hcfmusp.relation.referenceMockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033eng
hcfmusp.relation.referenceMonge-Ortega OP, 2018, J INVEST ALLERG CLIN, V28, P132, DOI 10.18176/jiaci.0220eng
hcfmusp.relation.referenceNARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154eng
hcfmusp.relation.referenceNatkunarajah J, 2011, EUR J DERMATOL, V21, P385, DOI 10.1684/ejd.2011.1300eng
hcfmusp.relation.referenceOh HL, 2019, ALLERGY ASTHMA IMMUN, V11, P241, DOI 10.4168/aair.2019.11.2.241eng
hcfmusp.relation.referenceOlteanu C, 2018, DRUG SAFETY, V41, P277, DOI 10.1007/s40264-017-0608-0eng
hcfmusp.relation.referenceParadisi A, 2014, J AM ACAD DERMATOL, V71, P278, DOI 10.1016/j.jaad.2014.04.044eng
hcfmusp.relation.referencePatmanidis Konstantinos, 2012, Case Rep Dermatol Med, V2012, P915314, DOI 10.1155/2012/915314eng
hcfmusp.relation.referencePichler WJ, 2011, J ALLERGY CLIN IMMUN, V127, pS74, DOI 10.1016/j.jaci.2010.11.048eng
hcfmusp.relation.referenceROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906eng
hcfmusp.relation.referenceRoujeau Jean-Claude, 1997, Journal of Dermatology (Tokyo), V24, P726eng
hcfmusp.relation.referenceSahnoun R, 2015, NEPHROL THER, V11, P111, DOI 10.1016/j.nephro.2014.11.004eng
hcfmusp.relation.referenceSaka B, 2019, DERMAT RES PRACT, V2019, DOI 10.1155/2019/4917024eng
hcfmusp.relation.referenceSassolas B, 2010, CLIN PHARMACOL THER, V88, P60, DOI 10.1038/clpt.2009.252eng
hcfmusp.relation.referenceSchneck J, 2008, J AM ACAD DERMATOL, V58, P33, DOI 10.1016/j.jaad.2007.08.039eng
hcfmusp.relation.referenceScott-Lang V, 2014, PEDIATR DERMATOL, V31, P532, DOI 10.1111/pde.12029eng
hcfmusp.relation.referenceShiohara Tetsuo, 2006, Allergol Int, V55, P1, DOI 10.2332/allergolint.55.1eng
hcfmusp.relation.referenceSidoroff A, 2007, BRIT J DERMATOL, V157, P989, DOI 10.1111/j.1365-2133.2007.08156.xeng
hcfmusp.relation.referenceSidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.xeng
hcfmusp.relation.referenceSu PQ, 2014, INT J DERMATOL, V53, P1339, DOI 10.1111/ijd.12118eng
hcfmusp.relation.referenceSultan SJ, 2015, INT J DERMATOL, V54, P537, DOI 10.1111/ijd.12331eng
hcfmusp.relation.referenceTorres MJ, 2009, J INVEST ALLERG CLIN, V19, P80eng
hcfmusp.relation.referenceTrent JT, 2003, ARCH DERMATOL, V139, P39, DOI 10.1001/archderm.139.1.39eng
hcfmusp.relation.referenceTristani-Firouzi P, 2002, J AM ACAD DERMATOL, V47, P548, DOI 10.1067/mjd.2002.127249eng
hcfmusp.relation.referenceDuong TA, 2017, LANCET, V390, P1996, DOI 10.1016/S0140-6736(16)30378-6eng
hcfmusp.relation.referenceWojtkiewiez A, 2008, ACTA DERM-VENEREOL, V88, P420, DOI 10.2340/00015555-0462eng
hcfmusp.relation.referenceWorsnop F, 2012, CLIN EXP DERMATOL, V37, P879, DOI 10.1111/j.1365-2230.2012.04357.xeng
hcfmusp.relation.referenceYang CY, 2011, NEUROLOGY, V77, P2025, DOI 10.1212/WNL.0b013e31823b478ceng
hcfmusp.relation.referenceZárate-Correa LC, 2013, J INVEST ALLERG CLIN, V23, P61eng
hcfmusp.relation.referenceZeng T, 2015, INT J DERMATOL, V54, P488, DOI 10.1111/ijd.12570eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication5aeba5b1-a416-4d64-931a-1d3750f77ad4
relation.isAuthorOfPublication966c3358-7bca-4de3-b1d1-b8efbce97c51
relation.isAuthorOfPublicatione5c9bf0c-59ec-4fcc-8bb5-001dabe25f0e
relation.isAuthorOfPublication.latestForDiscovery5aeba5b1-a416-4d64-931a-1d3750f77ad4
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/60